Feature | July 19, 2013

Mount Sinai Medical Center First in New York to Offer HeartMate II Pocket Controller

July 19, 2013 — The Mount Sinai Medical Center is the first medical center in New York City to offer the HeartMate II pocket controller, newly approved by the U.S. Food and Drug Administration (FDA), to help its advanced heart failure patients maintain more active lifestyles. This latest-generation controller for the HeartMate II left ventricular assist device (LVAD) is a new small, lightweight, patient-friendly external controller about the size of a smart phone that easily fits in a patient’s front pocket and powers their heart to pump.

“This new HeartMate II controller is a good step forward for our heart failure patients who are awaiting a heart transplant or in need of long-term, permanent support for their survival,” says Sean P. Pinney, M.D., director of the Advanced Heart Failure & Cardiac Transplantation Program at Mount Sinai. “With its smaller size and intuitive safety features, we expect the new controller will enhance the daily lives of our heart failure patients.”

Mount Sinai has one of the largest LVAD programs in the United States, with its cardiothoracic surgeons implanting approximately 50 each year. The center started using LVAD technology in 2006 for advanced heart failure patients. It is used as a bridge-to-transplant (BTT) therapy or destination therapy (DT) for permanent support. In addition, Mount Sinai performs dozens of successful heart transplants each year.

“This new controller will improve the LVAD patient’s overall experience [and] heighten the quality of their life by supporting their active lifestyle, while providing pocket-sized peace of mind for them and their clinical care team,” says Kimberly Ashley, FNP-BC, the VAD program manager for the Advanced Heart Failure & Cardiac Transplantation Program. “We hope to expand the use of this pocket-sized HeartMate II controller to not only new patients but also those current HeartMate II users to give them the option to swap out their old controller for the smaller, safer version, making their lives more comfortable and normal during their daily activities.”

The new patient-friendly controller is a small computer attached to the HeartMate II LVAD via one side cable. It enhances patients’ safety by powering their LVAD to pump their heart, monitoring their vital signs and alerting them of any concerns. Its new design features a diagnostic check system to make sure device wires are intact and functional, special visual alarms, precise onscreen instructions for the patient and longer backup battery power. In addition, the device is programmed with 37 languages to serve diverse patient populations.

“We do extensive patient education training before and after LVAD surgery to teach patients exactly how their controllers work, how to closely monitor their LVAD’s status and also to be vitally aware of any issues or concerns that may arise,” says Bess Griffin, RN, BSN, the VAD coordinator for the Advanced Heart Failure & Cardiac Transplantation Program. “The staff — who have begun training on the new, smart, smaller controller — really enjoy the device’s very easy, user-friendly interface. Thanks to the new controller we are expecting patients may be trained more quickly and feel more confident in caring for their device at home.”

The pocket controller is available for new advanced heart failure patients in need who receive HeartMate II, as well as for current HeartMate II patients who wish to upgrade their existing system controllers.

For more information: www.mountsinai.org

Related Content

Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Overlay Init